Aiming to bridge the longevity gap between breeds, Loyal, a pet longevity company, is on the verge of a veterinary breakthrough. They’re developing an injectable drug targeting the IGF-1 hormone, with the goal of extending the healthy lives of larger dogs by at least a year. Garnering support from the FDA for a fast-tracked authorization, Loyal is on track for a potential conditional approval of their drug, LOY-001, in 2026. This approval could allow the drug to reach the market even before the completion of extensive clinical trials, as shared by Founder and CEO, Celine Halioua.
Read original article at The New York Times